BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung Huh, M.D., Ph.D., BiPar's president and chief executive officer, will present information on BiPar's development programs and product pipeline, including the company's lead product candidate, BSI-201, which is in Phase 2 clinical trials, at the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA.
